| Schizophrenia

Cobenfy vs Latuda

Side-by-side clinical, coverage, and cost comparison for schizophrenia.

Deep comparison between: Cobenfy vs Latuda with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsLatuda has a higher rate of injection site reactions vs Cobenfy based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Latuda but not Cobenfy, including UnitedHealthcare

Category

Cobenfy

Latuda

At A Glance

RouteOral

FrequencyTwice daily

ClassMuscarinic agonist/antagonist combination

RouteOral

FrequencyOnce daily

ClassAtypical antipsychotic

Indications

Schizophrenia

Schizophrenia
Depression, Bipolar

Dosing

Schizophrenia Starting dose 50 mg/20 mg orally twice daily for at least 2 days, then 100 mg/20 mg twice daily for at least 5 days; may increase to 125 mg/30 mg twice daily based on tolerability and response (maximum dose); take at least 1 hour before or 2 hours after a meal; do not open capsules. Geriatric patients: start at 50 mg/20 mg twice daily, maximum 100 mg/20 mg twice daily.

Schizophrenia Adults: 40 mg once daily (range 40-160 mg/day); adolescents 13-17 years: 40 mg once daily (range 40-80 mg/day); take with food (at least 350 calories).

Depression, Bipolar Adults: 20 mg once daily as monotherapy or adjunctive therapy with lithium or valproate (range 20-120 mg/day); pediatric patients 10-17 years: 20 mg once daily as monotherapy (range 20-80 mg/day); take with food (at least 350 calories).

Contraindications

Urinary retention
Moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment
Gastric retention
History of hypersensitivity to COBENFY or trospium chloride
Untreated narrow-angle glaucoma

Known hypersensitivity to lurasidone HCl or any components in the formulation
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)
Concomitant use with strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine)

Drug Interactions

712View drug interactions

710View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease

Serious Urinary retention, liver enzyme elevations, increases in heart rate, angioedema

Postmarketing Chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope, gastritis, rash, rhabdomyolysis, confusion, delirium, hallucinations, somnolence, vision abnormal, angioedema, anaphylactic reaction, Stevens-Johnson syndrome (reported with trospium chloride component)

Most common (>=5%) Somnolence, akathisia, extrapyramidal symptoms, nausea, vomiting, diarrhea, anxiety

Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, cerebrovascular adverse reactions, hyperprolactinemia, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, body temperature dysregulation

Postmarketing Urticaria, throat swelling, tongue swelling, dyspnea, rash, hyponatremia

Pharmacology

Xanomeline is a muscarinic agonist with preferential activity at M1 and M4 receptors in the central nervous system, where its efficacy in schizophrenia is thought to arise; trospium chloride is a peripheral muscarinic antagonist included to reduce cholinergic adverse effects.

Lurasidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors and as a partial agonist at 5-HT1A receptors, with little affinity for histamine H1 or muscarinic M1 receptors; its efficacy in schizophrenia and bipolar depression may be mediated through combined D2 and 5-HT2A receptor antagonism.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cobenfy